黏液囊炎治療市場：依治療方法、產品類型、應用部位及最終用戶分類－2026-2032年全球市場預測

預計到 2025 年，黏液囊炎治療市場價值將達到 15.9 億美元，到 2026 年將成長至 17.3 億美元，到 2032 年將達到 31.5 億美元，複合年成長率為 10.23%。

主要市場統計數據
基準年 2025	15.9億美元
預計年份：2026年	17.3億美元
預測年份：2032年	31.5億美元
複合年成長率 (%)	10.23%

簡要介紹黏液囊炎的治療途徑、患者負擔、多學科護理以及影響現代臨床實踐的系統因素。

黏液囊炎是一種常見但常被低估的疼痛和功能障礙原因，影響著不同族群。臨床上，其症狀從急性發炎發作到慢性疾病不等，慢性疾病會限制活動，干擾工作和休閒。治療策略包括保守的自我護理、藥物治療、影像導引注射、復健治療，以及在某些情況下進行手術介入。人口老化、耐力運動和高強度運動參與度的提高，以及代謝性疾病和風濕性疾病合併症的高發生率等人口結構變化，使得疾病的治療路徑日益複雜。

變革性的臨床技術和供應趨勢正在重新定義黏液囊炎治療決策、護理服務模式和相關人員。

近年來，黏液囊炎的治療格局發生了重大變革，這主要得益於臨床創新、醫療服務水準的提高以及相關人員期望的轉變。再生醫學和生物目標療法的進步為傳統的皮質類固醇療法提供了替代方案，而成像技術和超音波引導技術的改進則提高了注射療法的精準性和安全性。同時，微創手術技術，特別是關節鏡手術，明確了手術治療的適應症，並縮短了合適患者的復原時間。

美國近期採取的關稅措施如何從採購、價格壓力、供應彈性和治療可用性等方面重塑整個黏液囊炎治療過程？

美國近期關稅調整對醫療用品和藥品整個價值鏈產生了連鎖反應，累積效應影響著治療方案的可近性、採購方式和成本結構。進口醫療設備、注射劑和生技藥品的關稅上漲增加了部分產品的接收成本，促使供應鏈相關人員重新評估其籌資策略。因此，一些製造商和經銷商正在加速供應商網路多元化，探索關鍵零件的近岸外包和回流生產，並協商替代貿易條款，以維持利潤率並確保向醫療機構穩定供應。

深入了解治療方法、產品分類、解剖適應症和臨床環境，將有助於闡明實施模式和臨床工作流程。

詳細的細分方法揭示了治療方法應用方式、最積極參與的相關人員以及創新集中的領域等方面的關鍵細微差別。從治療方式的角度觀點，治療方法範圍涵蓋了從居家照護（例如冰敷、休息/制動和熱敷）到藥物治療（包括非處方和處方非類固醇消炎劑），甚至注射療法（其中皮質類固醇注射仍然占主導地位，但也包括透明質酸和富血小板血漿療法等較新的選擇）。物理治療包括冷療、運動療法和手法治療，而外科手術通常分為關節鏡和開放性手術。在每個細分領域中都可以觀察到明顯的趨勢。在初期階段，由於優先考慮可及性和低成本，通常會採用保守的居家照護和口服藥物。然而，如果症狀持續存在或需要更積極的治療才能達到功能目標，通常會採用注射療法或手術介入。

主要全球市場臨床實踐模式、報銷方式、監管管道和供應鏈因素的關鍵區域差異影響著臨床引入。

區域趨勢對黏液囊炎的診斷、治療和報銷有顯著影響，各大區域呈現明顯的模式。在美洲，醫療服務傾向於優先考慮快速獲得介入治療和完善的門診管道。私人保險公司的組成以及門診手術中心的擴張影響注射療法和關節鏡手術的分佈。在歐洲、中東和非洲，由於報銷系統、管理體制以及先進生技藥品取得途徑的差異，醫療保健的差異性增加。在許多市場，集中採購和統一的國家指南影響著高成本治療的推廣，而公共醫療體系在製定標準治療方案方面發揮著至關重要的作用。在亞太地區，一些國家人口老化迅速，其他國家體育運動參與率高，這些人口趨勢推動了對保守治療和介入治療的需求。同時，製造地和區域供應鏈影響產品的供應和價格趨勢。

對競爭對手、策略夥伴關係關係和實證差異化在塑造黏液囊炎治療和服務商業性格局中的作用進行洞察和分析。

黏液囊炎治療領域的競爭格局呈現出多元化的格局，參與者包括成熟的製藥公司、醫療設備製造商、生技藥品和再生醫學專業開發商、數位醫療供應商以及支持分銷和臨床培訓的服務供應商。參與企業企業繼續利用其規模、臨床資源和豐富的產品系列，確保在醫院和門診中心獲得充足的市場佔有率。同時，小規模的專業公司則專注於利基創新，特別是再生醫學注射、照護現場生技藥品處理和新型給藥系統。此外，數位療法和遠距復健供應商也日益受到重視，他們能夠幫助患者長期堅持運動療法，並促進遠距臨床醫生的指導。

製造商、醫療保健提供者和支付方採用的實用、循證的策略建議，旨在提高臨床價值、供應彈性和以患者為中心的結果。

產業領導者和臨床專案經理應採取多管齊下的策略，以創造臨床價值、改善患者療效並降低商業性風險。首先，必須優先為新型注射劑和再生醫學方案建立高品質的實證醫學證據。將隨機對照試驗與可操作的真實世界研究相結合，將有助於與支付方合作並推動相關研究成果被納入指南。其次，供應鏈多元化並考慮關鍵部件的近岸外包，將有助於降低關稅波動和運輸中斷帶來的風險；同時，與集團採購商簽訂戰略契約，將有助於穩定價格和供應。第三，投資臨床醫生教育以及超音波引導注射和微創手術的系統化實施項目，將有助於規範操作並降低治療結果的差異性。

為了確保獲得可靠的見解，我們採用了嚴謹的混合調查方法，結合了專家訪談、臨床文獻整合、供應鏈分析和使用資料檢驗。

這些研究結果是基於多層次的調查方法，旨在從臨床實踐模式、採購行為和創新趨勢三個方面進行三角驗證。主要研究內容包括對骨科醫生、物理治療師、介入性疼痛專家、門診手術經理和保險公司醫療保健主管進行結構化訪談，以了解他們對治療方法選擇、實施障礙和營運限制的實際觀點。次要分析則利用同儕審查的臨床文獻、專業學會指南和監管文件，評估藥物治療、注射治療、復健和手術方法的比較證據依證。供應鏈圖譜和貿易數據分析揭示了採購方面的薄弱環節以及關稅波動對零件供應的潛在影響。

結論強調，臨床創新、醫療服務轉型、保險公司的壓力以及供應韌性相互交織，共同塑造黏液囊炎治療的未來。

總之，多種因素正在重塑黏液囊炎的治療格局：生技藥品和影像引導介入治療方法的創新、遠端醫療和居家醫療能力的提升、健康保險公司對療效和成本效益的日益重視，以及影響產品供應和定價的供應鏈壓力。這些趨勢為臨床和商業領域的相關人員帶來了挑戰和機會。臨床醫生需要在遵循實證實踐流程的同時整合新的治療方法，製造商需要展現明顯的比較優勢，而醫療保健系統則需要製定穩健的籌資策略，以確保患者能夠獲得完整的、持續的治療。

目錄

第1章：序言

第2章：調查方法

• 調查設計
• 研究框架
• 市場規模預測
• 數據三角測量
• 調查結果
• 調查的前提
• 研究限制

第3章執行摘要

• 首席主管觀點
• 市場規模和成長趨勢
• 2025年市佔率分析
• FPNV定位矩陣，2025
• 新的商機
• 下一代經營模式
• 工業藍圖

第4章 市場概覽

• 產業生態系與價值鏈分析
• 波特五力分析
• PESTEL 分析
• 市場展望
• 上市策略

第5章 市場洞察

• 消費者洞察與終端用戶觀點
• 消費者體驗基準
• 機會映射
• 分銷通路分析
• 價格趨勢分析
• 監理合規和標準框架
• ESG與永續性分析
• 中斷和風險情景
• 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：黏液囊炎治療市場：依治療類型分類

• 居家照護
  • 冰敷療法
  • 休息/固定
  • 熱敷
• 注射療法
  • 腎上腺皮質激素注射
  • 玻尿酸注射
  • 富血小板血漿療法
• 口服藥物
  • 非處方非類固醇消炎劑
  • 非類固醇消炎劑（NSAIDs）
• 物理治療
  • 冷凍療法
  • 運動療法
  • 手法治療
• 手術治療
  • 關節鏡手術
  • 開放性手術

第9章：黏液囊炎治療市場：依產品類型

• 抗生素
• 生技藥品
• 皮質類固醇
• 非類固醇消炎劑

第10章：黏液囊炎治療市場：依應用部位分類

• 彎頭
• 腳跟
• 髖關節
• 膝蓋
• 肩膀

第11章：黏液囊炎治療市場：依最終用戶分類

• 門診手術中心
• 居家照護設施
• 醫院
• 整形外科診所
• 運動醫學中心

第12章：黏液囊炎治療市場：依地區分類

• 北美洲和南美洲
  • 北美洲
  • 拉丁美洲
• 歐洲、中東和非洲
  • 歐洲
  • 中東
  • 非洲
• 亞太地區

第13章：黏液囊炎治療市場：依組別分類

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第14章：黏液囊炎治療市場：依國家分類

• 美國
• 加拿大
• 墨西哥
• 巴西
• 英國
• 德國
• 法國
• 俄羅斯
• 義大利
• 西班牙
• 中國
• 印度
• 日本
• 澳洲
• 韓國

第15章：美國黏液囊炎治療市場

第16章：中國黏液囊炎治療市場

第17章 競爭格局

• 市場集中度分析，2025年
  • 濃度比（CR）
  • 赫芬達爾-赫希曼指數 (HHI)
• 近期趨勢及影響分析，2025 年
• 2025年產品系列分析
• 基準分析，2025 年
• AbbVie Inc.
• Amgen Inc.
• Arinna Lifesciences Ltd.
• AstraZeneca PLC
• Bioanalytical Systems, Inc.
• Bristol-Myers Squibb Company
• Crescent Formulations Pvt.Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• NIDEK CO., LTD.
• Novartis AG
• Perrigo Company PLC
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.
• Topcon Corporation

The Bursitis Treatment Market was valued at USD 1.59 billion in 2025 and is projected to grow to USD 1.73 billion in 2026, with a CAGR of 10.23%, reaching USD 3.15 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 1.59 billion
Estimated Year [2026]	USD 1.73 billion
Forecast Year [2032]	USD 3.15 billion
CAGR (%)	10.23%

A concise introduction to bursitis treatment pathways, patient burden, multidisciplinary care, and the systemic forces shaping contemporary clinical practice

Bursitis represents a common yet often underestimated source of pain and functional limitation across diverse patient populations. In clinical practice, presentations range from acute inflammatory flares to chronic, activity-limiting conditions that impair work performance and recreational participation. Management strategies span conservative self-care measures, pharmacologic treatment, image-guided injections, rehabilitative interventions, and, in select cases, surgical procedures. Demographic shifts such as population aging, rising participation in endurance and high-impact sports, and persistent rates of comorbid metabolic and rheumatologic conditions have collectively increased the complexity of care pathways for this condition.

In addition, evolving expectations around rapid recovery, minimally invasive approaches, and minimized opioid exposure shape both clinician decision-making and payer scrutiny. Care delivery has also been altered by expanded remote care modalities; patients increasingly seek timely advice and guided rehabilitation that reduce the need for in-person visits. Moreover, the growing emphasis on outcomes, functional restoration, and cost-effective care has prompted multidisciplinary collaboration among primary care physicians, orthopedic specialists, physiotherapists, and pain management teams. This introduction sets the stage for a deeper examination of market dynamics, treatment innovations, reimbursement influences, and operational pressures that together define the contemporary landscape of bursitis treatment.

Transformative clinical, technological, and supply dynamics that are redefining treatment decisions, care delivery models, and stakeholder incentives in bursitis management

Over the last several years, the treatment landscape for bursitis has undergone substantive transformation driven by clinical innovation, care delivery evolution, and shifting stakeholder expectations. Advances in regenerative medicine and targeted biologic therapies have introduced alternatives to traditional corticosteroid approaches, while improved imaging techniques and ultrasound guidance have increased the precision and safety of injectable interventions. Concurrently, minimally invasive surgical techniques, particularly arthroscopic methods, have refined indications for operative management and reduced convalescence times for appropriate candidates.

Complementing therapeutic innovation, digital health enablers such as tele-rehabilitation platforms, remote monitoring, and patient-facing education tools have extended the reach of physical therapy and self-management programs. These tools are increasingly integrated into care pathways to support adherence to exercise therapy, facilitate clinician oversight, and provide real-time feedback on recovery trajectories. On the payer and provider sides, value-based contracting and outcome-focused procurement pressures are incentivizing evidence generation and cost-effectiveness studies, which in turn shape adoption patterns. Finally, supply chain volatility and an increased emphasis on domestic resilience are causing manufacturers and health systems to reassess sourcing strategies for implants, injectables, and home-care devices. Taken together, these shifts are moving the field toward more personalized, data-driven, and care-continuum-oriented approaches that prioritize measurable functional outcomes and patient experience.

How recent United States tariff measures are reshaping procurement, pricing pressures, supply resilience, and therapeutic availability across bursitis care pathways

Recent tariff changes in the United States have reverberated through the medical supply and pharmaceutical value chains, producing cumulative effects that influence treatment availability, procurement practices, and cost structures. Tariffs that affect imported medical devices, injectables, and biologic inputs increase the landed cost of certain products, prompting supply chain actors to reassess sourcing strategies. Consequently, some manufacturers and distributors have accelerated diversification of supplier networks, considered nearshoring or reshoring critical components, and negotiated alternative commercial terms to preserve margins and maintain consistent availability to providers.

Clinically, these procurement responses can influence the mix of therapies offered: higher device or biologic costs may lead health systems and outpatient centers to re-evaluate formularies and standard operating procedures, favoring therapeutics with stronger cost-effectiveness evidence or lower logistic complexity. For home-care modalities and over-the-counter products, tariff-driven price pressures can affect retail pricing and patient out-of-pocket burdens, which in turn shape adherence to noninvasive regimens. Additionally, tariff-induced cost volatility encourages buyers to leverage longer-term contracting, group purchasing organizations, and strategic inventory buffering to mitigate disruption.

At a strategic level, renewed policy-driven cost pressures stimulate investment in domestic manufacturing capacity, increase interest in alternative materials and technologies that bypass tariffed inputs, and intensify collaboration between clinicians, supply chain managers, and procurement teams. While tariffs do not directly change clinical efficacy, their secondary effects on availability, pricing, and procurement behavior can alter the landscape in which therapeutic choices are made, emphasizing resilience, evidence-backed value, and strategic contracting as key mitigation levers.

Clear segmentation-driven insights into therapeutic modalities, product classes, anatomical applications, and care settings that explain adoption patterns and clinical workflows

A granular segmentation lens reveals important nuances in how treatments are applied, which stakeholders are most active, and where innovation is concentrated. When treatments are viewed through the prism of therapy modality, care ranges from home-based measures-such as ice therapy, rest and immobilization, and warm compress applications-through pharmacologic approaches that include both over-the-counter and prescription nonsteroidal anti-inflammatory drugs, to injectable therapies where corticosteroid injections remain a mainstay and emerging options include hyaluronic acid and platelet-rich plasma therapy. Physical therapy practices encompass cryotherapy, exercise therapy, and manual therapy, while surgical interventions are generally divided between arthroscopic and open surgical approaches. Each of these subsegments demonstrates distinct patterns: conservative home care and oral medication often serve as initial steps that prioritize accessibility and low cost, whereas injectable therapy and surgical intervention are typically pursued when symptoms persist or functional goals demand more aggressive management.

From a product-category perspective, antibiotics, biologics, corticosteroids, and nonsteroidal anti-inflammatory drugs play discrete roles with differing regulatory profiles, evidence requirements, and distribution pathways. Biologics and advanced regenerative products, for example, require distinct cold-chain logistics and clinical training for administration compared with small-molecule NSAIDs. Considering anatomical application sites, treatment selection is influenced by structural variation across the elbow, heel, hip, knee, and shoulder; site-specific biomechanical demands and patient activity levels drive clinical decision-making and rehabilitation planning. Finally, the end-user landscape spans ambulatory surgical centers, home care settings, hospitals, orthopedic clinics, and sports medicine centers, each with unique purchasing processes, clinical workflows, and volume profiles. Understanding how these segmentation axes interact is essential for tailoring clinical protocols, commercial strategies, and evidence-generation programs to real-world use cases.

Key regional distinctions in practice patterns, reimbursement realities, regulatory pathways, and supply chain factors that influence clinical adoption across major global markets

Regional dynamics materially influence how bursitis is diagnosed, treated, and reimbursed, with distinct patterns emerging across major geographies. In the Americas, care delivery often emphasizes rapid access to interventional procedures and well-established outpatient pathways; private payer mix and ambulatory surgical center growth shape the distribution of injectable therapies and arthroscopic procedures. Moving to Europe, Middle East & Africa, practice variation is greater due to heterogeneous reimbursement systems, regulatory regimes, and access to advanced biologics; in many markets, centralized procurement and national guideline alignment influence the uptake of higher-cost therapeutics, and public systems play an outsized role in defining standard of care. Across the Asia-Pacific region, demographic trends-such as rapidly aging populations in some countries and high sports participation in others-drive demand for both conservative and interventional approaches, while manufacturing hubs and regional supply chains influence availability and pricing dynamics.

Across all regions, the pace of digital adoption, tele-rehabilitation, and training for ultrasound-guided injections varies, affecting the extent to which remote care or image-guided interventions are integrated into routine practice. Moreover, regional regulatory pathways for novel biologics and cell-based therapies determine the speed with which evidence is translated into clinical availability. Trade policies and logistics infrastructure further modulate the reliability of product supply, and regional differences in clinical guideline development and specialist density shape where care is concentrated, whether that be in hospital systems, specialty clinics, or community-based settings.

Insightful analysis of competitive roles, strategic partnerships, and evidence-driven differentiation shaping the commercial landscape for bursitis therapeutics and services

Competitive dynamics within the bursitis treatment ecosystem reflect a heterogeneous mix of established pharmaceutical manufacturers, medical device companies, specialty biologics and regenerative medicine developers, digital health vendors, and service providers that support distribution and clinical training. Incumbent players continue to leverage scale, clinical relationships, and broad product portfolios to maintain access across hospitals and ambulatory centers, while smaller specialty firms focus on niche innovations-particularly in regenerative injections, point-of-care biologic processing, and novel delivery systems. At the same time, digital therapeutics and tele-rehabilitation suppliers are increasing their relevance by enabling long-term adherence to exercise therapy and facilitating remote clinician oversight.

Strategic behavior includes targeted partnerships between device or biologic developers and clinical networks to generate real-world evidence and to accelerate guideline adoption. Contract manufacturing organizations and logistics specialists also play a pivotal role, particularly for temperature-sensitive biologics and single-use procedural kits. Across the competitive landscape, differentiation increasingly depends on the strength and transparency of clinical evidence, the quality of training and clinician support programs, and the ability to demonstrate consistent outcomes in routine practice. Companies that can integrate evidence generation with pragmatic implementation support, while also addressing payer concerns regarding cost-effectiveness, are positioned to gain preferential access to procurement decision-makers and long-term contracts.

Practical and evidence-focused strategic recommendations for manufacturers, providers, and payers to enhance clinical value, supply resilience, and patient-centered outcomes

Industry leaders and clinical program directors should adopt a multi-pronged strategy to capture clinical value, improve patient outcomes, and mitigate commercial risk. First, prioritizing high-quality evidence generation for novel injectables and regenerative options is essential; randomized controlled trials complemented by pragmatic real-world studies will support payer engagement and guideline inclusion. Second, diversifying supply chains and exploring nearshoring options for critical components can reduce exposure to tariff volatility and shipping disruptions, while strategic contracting with group purchasers can stabilize pricing and availability. Third, investing in clinician education and structured implementation programs for ultrasound-guided injections and minimally invasive procedures will facilitate appropriate adoption and reduce variability in outcomes.

Additionally, integrating tele-rehabilitation and patient-facing adherence tools into care pathways can improve functional recovery rates and reduce downstream utilization of invasive procedures. Value-based contracting models that link reimbursement to patient-reported outcomes and functional benchmarks should be explored with payers to align incentives around meaningful recovery. Finally, companies and providers should develop clear, patient-centered communication frameworks to set expectations for recovery timelines, nonpharmacologic management, and the trade-offs between short-term symptom relief and longer-term tissue healing, thereby enhancing shared decision-making and adherence to conservative regimens when appropriate.

A rigorous mixed-methods research methodology combining expert interviews, clinical literature synthesis, supply chain analysis, and utilization data triangulation to ensure robust findings

The research underpinning these insights combined a layered methodology designed to triangulate clinical practice patterns, procurement behaviors, and innovation trends. Primary inputs included structured interviews with orthopedists, physiotherapists, interventional pain specialists, ambulatory surgery managers, and payer medical directors to capture frontline perspectives on treatment selection, barriers to adoption, and operational constraints. Secondary analysis drew upon peer-reviewed clinical literature, professional society guidelines, and regulatory filings to assess the comparative evidence base for pharmacologic, injectable, rehabilitative, and surgical approaches. Supply chain mapping and trade data reviews were used to understand sourcing vulnerabilities and the potential impacts of tariff shifts on component availability.

Wherever possible, qualitative findings were cross-checked with anonymized claims and utilization datasets to validate patterns of service delivery and care transitions. The methodology prioritized transparency about limitations: for example, national-level heterogeneity in coding practices can complicate cross-country comparisons, and emerging biologic technologies may lack long-term outcome data. Ethical safeguards included informed consent for interviews and de-identification of proprietary procurement information. Taken together, this mixed-methods approach offers a robust foundation for the insights presented while acknowledging areas where further prospective data collection would strengthen causal inference.

Concluding synthesis highlighting the intersection of clinical innovation, care delivery transformation, payer pressures, and supply resilience shaping future bursitis care

In summary, the management of bursitis is being reshaped by converging forces: therapeutic innovation in biologics and image-guided interventions; expanding capability for remote and home-based care; heightened payer emphasis on outcomes and cost-effectiveness; and supply chain pressures that influence product availability and pricing. These dynamics create both challenges and opportunities for stakeholders across the clinical and commercial spectrum. Clinicians are tasked with integrating new modalities while maintaining evidence-based pathways, manufacturers must demonstrate clear comparative value, and health systems need to design resilient procurement strategies that support consistent access to a full continuum of care.

Moving forward, the most successful programs will be those that align rigorous clinical evidence with pragmatic implementation supports, leverage digital tools to enhance recovery and adherence, and proactively manage supply risk through diversified sourcing and strategic contracting. By focusing on measurable functional outcomes and patient-centered care, stakeholders can improve recovery trajectories while ensuring sustainable delivery models that are responsive to evolving regulatory and commercial conditions.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bursitis Treatment Market, by Treatment Type

• 8.1. Home Care
  • 8.1.1. Ice Therapy
  • 8.1.2. Rest Immobilization
  • 8.1.3. Warm Compress
• 8.2. Injectable Therapy
  • 8.2.1. Corticosteroid Injections
  • 8.2.2. Hyaluronic Acid Injections
  • 8.2.3. Platelet-Rich Plasma Therapy
• 8.3. Oral Medication
  • 8.3.1. Over-The-Counter Nonsteroidal Anti-Inflammatory Drugs
  • 8.3.2. Prescription Nonsteroidal Anti-Inflammatory Drugs
• 8.4. Physical Therapy
  • 8.4.1. Cryotherapy
  • 8.4.2. Exercise Therapy
  • 8.4.3. Manual Therapy
• 8.5. Surgical Intervention
  • 8.5.1. Arthroscopic Surgery
  • 8.5.2. Open Surgery

9. Bursitis Treatment Market, by Product Category

• 9.1. Antibiotics
• 9.2. Biologics
• 9.3. Corticosteroids
• 9.4. Nonsteroidal Anti-Inflammatory Drugs

10. Bursitis Treatment Market, by Application Site

• 10.1. Elbow
• 10.2. Heel
• 10.3. Hip
• 10.4. Knee
• 10.5. Shoulder

11. Bursitis Treatment Market, by End User

• 11.1. Ambulatory Surgical Centers
• 11.2. Home Care Settings
• 11.3. Hospitals
• 11.4. Orthopedic Clinics
• 11.5. Sports Medicine Centers

12. Bursitis Treatment Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Bursitis Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Bursitis Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Bursitis Treatment Market

16. China Bursitis Treatment Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. AbbVie Inc.
• 17.6. Amgen Inc.
• 17.7. Arinna Lifesciences Ltd.
• 17.8. AstraZeneca PLC
• 17.9. Bioanalytical Systems, Inc.
• 17.10. Bristol-Myers Squibb Company
• 17.11. Crescent Formulations Pvt.Ltd.
• 17.12. Eli Lilly and Company
• 17.13. F. Hoffmann-La Roche Ltd.
• 17.14. GlaxoSmithKline plc
• 17.15. Johnson & Johnson Services, Inc.
• 17.16. Merck & Co., Inc.
• 17.17. NIDEK CO., LTD.
• 17.18. Novartis AG
• 17.19. Perrigo Company PLC
• 17.20. Pfizer Inc.
• 17.21. Sanofi S.A.
• 17.22. Sun Pharmaceutical Industries Limited
• 17.23. Teva Pharmaceutical Industries Ltd.
• 17.24. Topcon Corporation

LIST OF FIGURES

• FIGURE 1. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BURSITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
• FIGURE 3. GLOBAL BURSITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
• FIGURE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
• FIGURE 11. UNITED STATES BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 12. CHINA BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

• TABLE 1. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 2. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 3. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 6. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 11. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 12. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 13. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 14. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 15. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 16. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 17. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 18. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 19. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 20. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 21. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 22. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 23. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 24. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 25. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 26. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 27. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 28. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 29. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 30. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 31. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 32. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 33. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 34. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 35. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 36. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 37. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 38. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 39. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 40. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 41. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 42. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 43. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 44. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 45. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 46. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 47. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 48. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 49. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 50. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 51. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 52. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
• TABLE 53. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 54. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 55. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 56. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 57. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 58. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 59. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2032 (USD MILLION)
• TABLE 60. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 61. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 62. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 63. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 64. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 65. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 66. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 67. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 68. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 69. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 70. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 71. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 72. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 73. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 74. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 75. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 76. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY REGION, 2018-2032 (USD MILLION)
• TABLE 77. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 78. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 79. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY REGION, 2018-2032 (USD MILLION)
• TABLE 80. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 81. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 82. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY REGION, 2018-2032 (USD MILLION)
• TABLE 83. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 84. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 85. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 86. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 87. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 88. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY REGION, 2018-2032 (USD MILLION)
• TABLE 89. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 90. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 91. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 92. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 93. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 94. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 95. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 96. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 97. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 98. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 99. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 100. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 101. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 102. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 103. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 104. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY REGION, 2018-2032 (USD MILLION)
• TABLE 105. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 106. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 107. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
• TABLE 108. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 109. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 110. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 111. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 112. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 113. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 114. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 115. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 116. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 117. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 118. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 119. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 120. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 121. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 122. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 123. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 124. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 125. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 126. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 127. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 128. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 129. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 130. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 131. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 132. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 133. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 134. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 135. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 136. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 137. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 138. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
• TABLE 139. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 141. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 142. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 143. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 144. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 145. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 146. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 147. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 148. EUROPE BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 149. EUROPE BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 150. EUROPE BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 151. EUROPE BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 152. EUROPE BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 153. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 154. EUROPE BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 155. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 156. EUROPE BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 157. EUROPE BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 158. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 159. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 160. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 161. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 162. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 163. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 164. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 165. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 166. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 167. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 168. AFRICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 169. AFRICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 170. AFRICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 171. AFRICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 172. AFRICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 173. AFRICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 174. AFRICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 175. AFRICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 176. AFRICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 177. AFRICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 178. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 179. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 180. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 181. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 182. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 183. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 184. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 185. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 186. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 187. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 188. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
• TABLE 189. ASEAN BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 190. ASEAN BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 191. ASEAN BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 192. ASEAN BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 193. ASEAN BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 194. ASEAN BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 195. ASEAN BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 196. ASEAN BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 197. ASEAN BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 198. ASEAN BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 199. GCC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 200. GCC BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 201. GCC BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 202. GCC BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 203. GCC BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 204. GCC BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 205. GCC BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 206. GCC BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 207. GCC BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 208. GCC BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 209. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 210. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 211. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 212. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 213. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 214. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 215. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 216. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 217. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 218. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 219. BRICS BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 220. BRICS BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 221. BRICS BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 222. BRICS BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 223. BRICS BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 224. BRICS BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 225. BRICS BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 226. BRICS BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 227. BRICS BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 228. BRICS BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 229. G7 BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 230. G7 BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 231. G7 BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 232. G7 BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 233. G7 BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 234. G7 BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 235. G7 BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 236. G7 BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 237. G7 BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 238. G7 BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 239. NATO BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 240. NATO BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 241. NATO BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 242. NATO BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 243. NATO BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 244. NATO BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 245. NATO BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 246. NATO BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 247. NATO BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 248. NATO BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 249. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
• TABLE 250. UNITED STATES BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 251. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 252. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 253. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 254. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 255. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 256. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 257. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 258. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 259. UNITED STATES BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
• TABLE 260. CHINA BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
• TABLE 261. CHINA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
• TABLE 262. CHINA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2032 (USD MILLION)
• TABLE 263. CHINA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2032 (USD MILLION)
• TABLE 264. CHINA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2032 (USD MILLION)
• TABLE 265. CHINA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2032 (USD MILLION)
• TABLE 266. CHINA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2032 (USD MILLION)
• TABLE 267. CHINA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2032 (USD MILLION)
• TABLE 268. CHINA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2032 (USD MILLION)
• TABLE 269. CHINA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)